Nymox Reports Positive Results Showing That NX-1207 Treatment for Prostate Cancer Does Not Affect Testosterone Levels
May 13 2014 - 9:45AM
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported today
positive new study findings showing that the Company's NX-1207
Phase 2 treatment for localized low-risk prostate cancer did not
affect testosterone levels in treated men. Analysis of testosterone
levels post-treatment for men treated with NX-1207 2.5 mg (n=47) or
15 mg (n=46) showed no statistically significant change as compared
to control active surveillance patients (n=48). This data is
consistent with the large body of existing data for men treated
with NX-1207 (n over 1,000) showing a favorable sexual profile for
the treatment.
One of the major problems with current prostate treatments for
localized prostate cancer (radical prostatectomy, external beam
radiation, or brachytherapy) is the relatively high incidence of
reported sexual dysfunction post-treatment. In now 8 completed
studies, NX-1207 treatment has shown to have no significant adverse
effect post-treatment on sexual function or testosterone
levels.
For the NX03-0040 study, previously reported study results
showed that patients with NX-1207 treatment had significantly less
Gleason grade progression, lower average PSA levels, lower numbers
of biopsy cores showing greater malignancy, and lower total volume
of more malignant cancer compared to controls.
To date, NX-1207 has had an excellent safety profile as both a
treatment for benign prostatic hyperplasia (BPH) and localized
low-risk prostate cancer. In the current trial, a new high dose of
drug (15 mg) was safely used without drug-related adverse effects.
NX-1207 has shown safety in repeat injection studies (NX02-0020 and
NX02-0022). The drug does not lead to immune responses such as
antibody formation which can cause significant drug toxicity and/or
limit usage to single treatments due to drug neutralizing
effects.
NX-1207 is in Phase 3 development in the US and Europe for
benign prostatic hyperplasia (BPH) also referred to as prostate
enlargement, a common affliction of middle-aged and elderly men,
affecting up to half of men over the age of 50. The Company's
European partner for BPH is Recordati S.p.A.
More information about Nymox is available at www.nymox.com,
email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements"
as defined in the United States Private Securities Litigation
Reform Act of 1995 that involve a number of risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and the actual results and future events could
differ materially from management's current expectations. Such
factors are detailed from time to time in Nymox's filings with the
United States Securities and Exchange Commission and other
regulatory authorities.
CONTACT: Brian Doyle
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2023 to Apr 2024